KURN 📈 Kuros Biosciences - Overview
Exchange: SW • Country: Switzerland • Currency: CHF • Type: Common Stock • ISIN: CH0325814116
KURN: Bone Grafts, Pharmaceuticals, Medical Devices
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through three segments: Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold use to fill bony voids for a predictable fusion; MagnetOs Easypack Putty, a ready-to-use mold to be implanted in any intervertebral disc space or posterolateral spine level; and Magnetos Flex Matrix, an open matrix bone graft. Its Fibrin-PTH pipeline products comprise KUR-111 and KUR-113 that are in Phase 2b clinical trials for trauma indications; KUR-113 that is in Phase 2a clinical trial for spinal indications. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland. Web URL: https://www.kuros.ch
Additional Sources for KURN Stock
KURN Stock Overview
| Market Cap in USD | 839m |
| Sector | Healthcare |
| Industry | Medical Devices |
| GiC Sub-Industry | Health Care Equipment |
| IPO / Inception |
KURN Stock Ratings
| Growth 5y | 73.9% |
| Fundamental | -25.8% |
| Dividend | - |
| Rel. Strength Industry | 14372 |
| Analysts | - |
| Fair Price Momentum | 22.51 CHF |
| Fair Price DCF | - |
KURN Dividends
No Dividends PaidKURN Growth Ratios
| Growth Correlation 3m | 11% |
| Growth Correlation 12m | 97.2% |
| Growth Correlation 5y | 28.7% |
| CAGR 5y | 54.85% |
| CAGR/Mean DD 5y | 2.07 |
| Sharpe Ratio 12m | 2.72 |
| Alpha | 521.07 |
| Beta | 0.59 |
| Volatility | 78.05% |
| Current Volume | 110.7k |
| Average Volume 20d | 226.8k |
What is the price of KURN stocks?
As of December 26, 2024, the stock is trading at CHF 20.20 with a total of 110,719 shares traded.
Over the past week, the price has changed by -1.46%, over one month by -14.04%, over three months by +10.50% and over the past year by +539.24%.
As of December 26, 2024, the stock is trading at CHF 20.20 with a total of 110,719 shares traded.
Over the past week, the price has changed by -1.46%, over one month by -14.04%, over three months by +10.50% and over the past year by +539.24%.
Is Kuros Biosciences a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Kuros Biosciences (SW:KURN) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -25.81 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of KURN as of December 2024 is 22.51. This means that KURN is currently undervalued and has a potential upside of +11.44% (Margin of Safety).
Probably not. Based on ValueRay Fundamental Analyses, Kuros Biosciences (SW:KURN) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -25.81 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of KURN as of December 2024 is 22.51. This means that KURN is currently undervalued and has a potential upside of +11.44% (Margin of Safety).
Is KURN a buy, sell or hold?
Kuros Biosciences has no consensus analysts rating.
Kuros Biosciences has no consensus analysts rating.
What are the forecast for KURN stock price target?
According to ValueRays Forecast Model, KURN Kuros Biosciences will be worth about 24.7 in December 2025. The stock is currently trading at 20.20. This means that the stock has a potential upside of +22.28%.
According to ValueRays Forecast Model, KURN Kuros Biosciences will be worth about 24.7 in December 2025. The stock is currently trading at 20.20. This means that the stock has a potential upside of +22.28%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 20.1 | -0.7% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 24.7 | 22.3% |